FOXP3 and neoplasm: In addition, tumor-associated immune response (CD3, p = 0.04; CD45ro, p = 0.03; FoxP3, p = 0.05)) and frontal tumor location (p = 0.01) were associated with longer overall survival (OS) in female patients.